**NMA on PTSD**

**Appendix 14**

NMA results (effect estimates and SUCRAs) for the primary efficacy outcome (change in symptoms) according to the standard analysis and the model that accounted for baseline severity.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Treatment** | **EFFECT ESTIMATES** | | **SUCRAs** | |
| **Standard analysis** | **Model that accounts for baseline severity (95% CI)** | **Standard analysis** | **Model that accounts for baseline severity** |
| Phenelzine | **0.97 (0.27, 1.68)** | **1.12 (0.41, 1.81)** | 93.8 | 95.3 |
| Mirtazapine | 0.79 (-0.09, 1.66) | 0.79 (-0.04, 1.63) | 84.1 | 82.8 |
| Desipramine | **0.52 (0.02, 1.02)** | 0.41 (-0.55, 1.39) | 75.6 | 60.3 |
| Olanzapine | 0.51 (-0.03, 1.06) | 0.53 (-0.01, 1.08) | 74.2 | 72.7 |
| Brofaromine | 0.47 (-0.12, 1.06) | 0.47 (-0.16, 1.11) | 69.3 | 67.7 |
| Paroxetine | **0.38 (0.21, 0.55)** | 0.27 (-0.52, 1.08) | 67.6 | 50.1 |
| Venlafaxine ER | **0.32 (0.12, 0.52)** | 0.34 (-0.09, 0.77) | 59.9 | 59.0 |
| Amitriptyline | 0.34 (-0.32, 1.01) | - | 59.1 | - |
| Fluoxetine | **0.30 (0.09, 0.51)** | **0.30 (0.06, 0.56)** | 57.3 | 56.5 |
| Imipramine | 0.27 (-0.39, 0.92) | 0.42 (-0.36, 1.15) | 51.4 | 61.2 |
| Topiramate | 0.29 (-0.14, 0.71) | 0.29 (-0.15, 0.72) | 54.9 | 53.6 |
| Risperidone | **0.27 (0.01, 0.54)** | 0.27 (-0.03, 0.59) | 54.3 | 52.1 |
| Nefazodone | 0.23 (-0.29, 0.76) | 0.27 (-0.27, 0.82) | 49.4 | 51.0 |
| Sertraline | **0.23 (0.09, 0.38)** | **0.27 (0.05, 0.50)** | 48.8 | 51.9 |
| NK1R antagonist | 0.20 (-0.15, 0.56) | - | 45.9 | - |
| Guanfacine | 0.12 (-0.33, 0.58) | 0.17 (-0.32, 0.66) | 38.5 | 42.2 |
| Tiagabine | 0.02 (-0.33, 0.37) | -0.01 (-0.46, 0.45) | 26.8 | 25.1 |
| Bupropion SR | -0.10 (-0.91, 0.71) | - | 25.4 | - |
| Placebo | Reference | Reference | 21.7 | 22.5 |
| Prazosin | -0.06 (-0.32, 0.20) | -0.10 (-0.60, 0.40) | 18.3 | 19.2 |
| Divalproex | -0.13 (-0.55, 0.28) | -0.11 (-0.58, 0.34) | 15.4 | 17.9 |
| Citalopram | -0.33 (-0.90, 0.24) | -0.32 (-0.93, 0.28) | 8.2 | 8.8 |

**Table.** NMA results (effect estimates and SUCRAs) for the primary efficacy outcome (change in symptoms) according to the standard analysis and the model that accounted for baseline severity. Values greater than 0 indicate that the active treatment is more efficacious. Underlined results indicate statistical significance. Lamotrigine is not included in this table because the primary study did not report data for this outcome (see Appendix 5). The effect estimates and the treatment ranking for the model that accounts for baseline severity correspond to the centralized mean of the baseline severity. Studies that do not report on the baseline severity are excluded from this analysis.